Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

s and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-nave group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

The treatment regimen was generally well-tolerated, as only non-severe side effects were observed, including diarrhea, fatigue, chest infection, rash, nausea, joint pain, and infrequent and transient low blood counts. Investigators found no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients. These results demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL.

"As we learn more about how to target specific essential survival signa
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 31, 2014 This ... has amazing health effects for practitioners. , ... a Doctor of Science and Movement specializing in ... dedication to pelvic floor reeducation that traditional abdominal ... incontinence, Diastasis Recti, Prolepses, etc. , The Hipopressives ...
(Date:10/31/2014)... News) -- Surgery for low back pain caused by ... States you live, a new report says. "Nearly ... at some point in their lives, and about 30 ... a spine problem," co-author Brook Martin, of the Dartmouth ... a college news release. In spinal stenosis, thickening ...
(Date:10/31/2014)... older Americans say that either they or a family ... to the latest issue of The Gerontological Society of ... PP&AR ), which goes on to show that Americans ... honor patients, end-of-life health care wishes. , This ... Options ," features 12 articles that present new ways ...
(Date:10/31/2014)... October 31, 2014 Urban Hydroponics, Inc. ... today announced it has signed a Binding Letter of ... the urban cultivation sector - Urban Cultivator Inc. (“Urban ... and W3 Metal Inc. (“W3 Metal” and together with ... Pursuant to the LOI and an earlier non-binding ...
(Date:10/31/2014)... Triple Board Certified surgeon Dr. Jeffrey ... transform the appearance of military veteran Joseph Jones. ... Plastic and Reconstruction Surgery (AAFPRS) Faces of Honor program, ... hair Jones lost during an IED blast almost ten ... procedure, valued around $16,000, took Dr. Epstein over eight ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
... doctors,and six others have been charged in four ... schemes totaling $56 million, the Department of,Justice Criminal ... of Florida announced today., One indictment alleges ... Harris, 57, and Enrique Gonzalez, 62, conspired to ...
... hospitals, physicians,pharmaceutical companies, and insurance providers that make ... spending $55 billion on,telecommunications services over the next ... by the Insight Research Corporation. According to,the market ... on,telecommunications services will grow at a compounded rate ...
... 29 GNC wants to help honorably,discharged veterans ... program., The program is designed to help ... next journey in life. Through Dec. 31, 2008, ... normal franchise fee.,Service-disabled veterans receive additional benefits, including ...
... May 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... has joined the company as Vice President, ... in the development and,execution of clinical and ... product candidates. Dr. Clarke was most recently,Vice ...
... May 29, 2008 Aging dental bridges are a maintenance headache ... to floss, often decay, and require replacement with longer bridges. ... to nowhere should be replaced with permanent dental implants. ... bridges in our mouths for twenty years or more. They ...
... 2007 ... date in 2008, VANCOUVER, May 29 /PRNewswire-FirstCall/ - CRH Medical ... three months ended March 31, 2008 compared to $0.50 million for ... Company,s net,loss decreased to $0.96 million ($0.02 per share) for the ...
Cached Medicine News:Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 2Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 3Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 4Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 5Health News:Healthcare Industry Spending on Telecommunications Services Hits $55 Billion Over Next Five Years, Says Insight Research 2Health News:Veterans to Receive Business Discounts Through GNC's New Veterans Franchising Opportunity 2Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 2Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 3Health News:Dental implants preferred option for aging bridges 2Health News:CRH Medical reports Q1 2008 results 2Health News:CRH Medical reports Q1 2008 results 3Health News:CRH Medical reports Q1 2008 results 4
(Date:10/31/2014)... 31, 2014 ThynkWare ( www.thynkware.com ) is ... text and email messages using their thoughts. ... by ThynkWare,s founder, Duane Cash , which is ... This technology allows users to control their devices in ... thought. ThynkWare provides the interface layer between ...
(Date:10/31/2014)... Oct. 30, 2014 Migranade, Inc. announced today ... available to the 36 million U.S. migraine sufferers November, ... that targets the actual cause of migraines and not ... and not the source Migranade is assured to be ... Migraine Relief is available at http://www.migranade.com and ...
(Date:10/31/2014)... 31, 2014  AbbVie (NYSE: ABBV ... quarter ended Sept. 30, 2014. ... our business with double-digit growth from HUMIRA and ... nearly 14 percent in the quarter excluding lipids," ... officer, AbbVie.  "We exceeded our outlook for the ...
Breaking Medicine Technology:ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
... WASHINGTON, Sept. 16 Policymakers and market leaders looking for ... are looking to the medical home to advance quickly and ... will converge on Washington, DC, Oct. 21, 2010 to examine ... means to deliver health care with better quality outcomes and ...
... Files New Patent Applications -- SHANGHAI, Sept. 16 /PRNewswire-Asia-FirstCall/ -- ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Medicine Technology:Patient-Centered Primary Care Collaborative Convenes Annual Summit 2Patient-Centered Primary Care Collaborative Convenes Annual Summit 3China-Biotics Files New Patent Applications 2China-Biotics Files New Patent Applications 3China-Biotics Files New Patent Applications 4China-Biotics Files New Patent Applications 5China-Biotics Files New Patent Applications 6China-Biotics Files New Patent Applications 7
... WaveScan WaveFront System is an ophthalmic diagnostic ... wavefront aberrations of the human eye using ... be used to determine regular (sphero-cylindrical) refractive ... or blurry vision in the human eye. ...
... Trusted technology. Precisely measured. ... precision diagnostics, measuring refractive error ... of the eye. ,As part ... Zyoptix™ Diagnostic Workstation, Zywave II ...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: